Trial Profile

GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itacitinib (Primary) ; Methylprednisolone; Prednisone
Indications Graft-versus-host disease
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms GRAVITAS-309
Sponsors Incyte Corporation

Most Recent Events

13 Mar 2024 This trial has been completed in Sweden, according to European Clinical Trials Database record.
23 Jan 2024 Status changed from active, no longer recruiting to discontinued (due to insufficient efficacy to support moving into Part 2 of thestudy).
13 Jan 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com